Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. As the leader in the Chinese diabetes market, Novo Nordisk has always been committed to changing diabetes. The unrelenting development of Novo Nordisk in China directly reflects the Company’s long-term commitment to the Chinese market.